NexgenRX Inc. (NXG) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NexgenRX Inc. stock C$0.73, price C$0.66, upside +10.0%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range C$0.1804 – C$0.7300 · fair‑value band C$0.5445 – C$0.9075 · the C$0.6600 price screens below the C$0.7260 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow NexgenRX in your weekly email
Every Wednesday you see whether NexgenRX is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada.
Show moreShow less
The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
Stock analysis
NexgenRX Inc. (NXG) currently trades at C$0.6600, while our model-based Fair Value estimate is C$0.7260, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of C$1.26 per share, and 11 of the 26 models we run sit above the C$0.6600 price.
Bear case: the Earnings-Based group reads lowest at C$0.3050, and 15 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: C$0.5445 (bear) to C$0.9075 (bull), the price of C$0.6600 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NexgenRX Inc. reported revenue of C$17.9M in FY2025 versus C$11.8M in FY2021, a compound +10.9%/yr. Reported net income was C$1.3M in FY2025, compounding −24.7%/yr from FY2021.
Key figures
Market cap C$46.9M (≈ $33.2M) Micro · P/E ratio 22.0 · P/S ratio 2.43 · EPS (TTM) C$0.0300 · Dividend yield 2.3% · Net margin 13.6% · Return on equity 30.1% · Return on assets (EBIT) 3.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 117% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at 10%, NXG screens cheaper than that median.
Fair Value models
BearC$0.5445Fair Value C$0.7260BullC$0.9075
Price C$0.6600 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.0128 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Start year 2020 (pandemic). Over 10 years: +14.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.1%
Dividend (yield on the price)2.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−16.1% vs 6.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −9.4% a year for the price.
AI conclusion: Its independent proprietary SaaS platform supports ongoing dividend payments from health benefits administration, yet small scale and absent durable advantages leave sustainability unclear.
Main risk: Larger competitors with broader networks may capture market share from its independent SaaS offering in Canadian plan administration, pressuring recurring cash flows.
NexgenRx continues paying dividends, with the third one this year tied directly to its improving results in health benefits administration. Its proprietary SaaS platform handles eligibility, enrolment and real-time claims for Canadian plan sponsors as an independent provider. Will that focused technology and independence sustain the cash flow, or will larger competitors with broader networks take share?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (12 months)30.1% · Top 25%
Return on assets3.5% · Above median
Net margin (12 months)13.6% · Top 25%
Operating margin (12 months)19.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)20.8% · Above median
Dividend yield (12 months)2.3% · Above median
Balance sheet
Debt / equity0.04× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NexgenRX Inc. Fair Value". https://www.fairvalue-calculator.com/stock/NXG
Frequently asked questions
Is NexgenRX Inc. (NXG) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of C$0.7260 versus a price of C$0.6600, about +10% upside (fairly valued).
What is the fair value of NXG?
Our model-based fair value for NexgenRX Inc. is C$0.7260 (as of Nov 6, 2026), built from audited fundamentals. The current price: C$0.6600.
What is the quality score of NXG?
NexgenRX Inc. has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NexgenRX Inc. (NXG)?
Our model-based price target is the fair value of C$0.7260 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario C$0.5445, optimistic scenario C$0.9075. It is a calculation from audited fundamentals, not an analyst target.
What is the NexgenRX Inc. stock forecast for 2026?
Our models put fair value at C$0.7260, about +10% upside versus a price of C$0.6600 (fairly valued). Cautious scenario C$0.5445, optimistic scenario C$0.9075. The calculation is refreshed regularly with new filings.
What is the revenue of NexgenRX Inc. (NXG)?
NexgenRX Inc. reported trailing-twelve-month revenue of about C$19.3M (latest available figure, as of Nov 6, 2026).
Does NexgenRX Inc. pay a dividend?
NexgenRX Inc. currently shows a dividend yield of 2.27% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of NexgenRX Inc. (NXG) and when is the ex-dividend date?
NexgenRX Inc. pays a dividend of C$0.015 per share a year, a dividend yield of 2.3%. The last ex-dividend date was Nov 2, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 50.0% of earnings. Free cash flow covers the dividend 4.34 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into NexgenRX Inc. (NXG)?
For today's price to be fair in a discounted-cash-flow model, NexgenRX Inc. would have to grow free cash flow by -7.5 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of NXG use?
Our models discount NexgenRX Inc. at 8.3 %: a base by market capitalisation (nano), damped by beta 0.46, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NexgenRX Inc. that is -7.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has NexgenRX Inc. (NXG) delivered so far?
Over the past 5 years revenue at NexgenRX Inc. grew +10.2 % a year. The price currently implies free-cash-flow growth of -7.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NexgenRX Inc. (NXG) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into NexgenRX Inc. (-7.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NexgenRX Inc. (NXG)?
The free-cash-flow yield on the price is 9.87 %: that much free cash flow NexgenRX Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NexgenRX Inc. (NXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NexgenRX Inc. it is C$0.7260 per share (as of Nov 6, 2026), against a price of C$0.6600. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is NexgenRX Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, NXG trades below its calculated fair value: price C$0.6600, fair value C$0.7260, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NXG?
No. The price is what the market pays today (C$0.6600); the fair value is what the company's own numbers justify (C$0.7260). For NexgenRX Inc. the two are C$0.0660 per share apart. That gap is exactly why we show both numbers side by side.
How much is NexgenRX Inc. worth?
The market values NexgenRX Inc. at about C$46.9M (market capitalisation, as of Nov 6, 2026). Per share that is C$0.6600; our models calculate a fair value of C$0.7260 per share.
What do the bullish and bearish scenarios say about NXG?
Our models span a range for NexgenRX Inc.: cautious scenario C$0.5445, base C$0.7260, optimistic C$0.9075 per share (as of Nov 6, 2026, price C$0.6600). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NXG?
NexgenRX Inc. trades at a price-to-earnings ratio of 22.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.7260 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2016 to 2025), reported earnings: 22.1. Other multiples: PEG 6.5, P/B 6.2, P/S 2.4, EV/EBITDA 12.8.
What is the PEG ratio of NXG?
The PEG ratio of NexgenRX Inc. is 6.53 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of NexgenRX Inc. (NXG)?
Balance-sheet figures for NexgenRX Inc. (as of Nov 6, 2026): return on equity 30.1%, debt of 0.04 per unit of equity. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is NXG from its 52-week high?
NexgenRX Inc. trades at C$0.6600, about 10% below its 52-week high of C$0.7300 and 117% above the low of C$0.3035 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.7260 is for.
Which stocks are comparable to NexgenRX Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NexgenRX Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price C$0.6600, calculated fair value C$0.7260 (+10%), Quality Score 73/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NXG calculated?
We run NexgenRX Inc. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of C$0.7260 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. NexgenRX Inc. currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NexgenRX Inc. (NXG)?
The closing price on Nov 6, 2026 was C$0.6600. Our model-based fair value is C$0.7260, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NexgenRX Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of NexgenRX Inc.
How large is the market capitalisation of NexgenRX Inc. (NXG)?
The market capitalisation of NexgenRX Inc. is C$46.9M (≈ $33.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NexgenRX Inc. (NXG)?
The price-to-sales ratio of NexgenRX Inc. is 2.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NexgenRX Inc. (NXG)?
Earnings per share at NexgenRX Inc. are C$0.0300 (price ÷ EPS = P/E 22.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NexgenRX Inc. (NXG)?
The dividend yield of NexgenRX Inc. is 2.3% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NexgenRX Inc. (NXG)?
The net margin of NexgenRX Inc. is 13.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NexgenRX Inc. (NXG)?
The return on equity (ROE) of NexgenRX Inc. is 30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NexgenRX Inc. (NXG)?
On an EBIT basis the return on assets of NexgenRX Inc. is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NexgenRX Inc. (NXG)?
The operating margin of NexgenRX Inc. is 19.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NexgenRX Inc. (NXG)?
Revenue at NexgenRX Inc. is growing +20.8% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NexgenRX Inc. (NXG)?
Earnings per share at NexgenRX Inc. are growing +140% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch NexgenRX Inc. in the live analysis
One click puts NexgenRX Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026